Keros Therapeutics (KROS) said Wednesday it has voluntarily halted all dosing in its phase 2 TROPOS trial for cibotercept in patients with pulmonary arterial hypertension due to "new observations of pericardial effusion adverse events."
The decision includes all treatment arms, including the 1.5 mg/kg and placebo groups.
Keros Therapeutics halted higher dose treatments of 3.0 mg/kg and 4.5 mg/kg last December due to similar concerns.
Keros Therapeutics shares were down more than 16% in recent premarket activity.
Price: 10.39, Change: -2.09, Percent Change: -16.75
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。